Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation Journal Article
| Authors: | Taranto, E.; Redd, R.; Jeter, E.; McHugh, K.; Crombie, J. L.; Fisher, D. C.; Jacobsen, E.; Jacobson, C. A.; Kim, A. I.; LaCasce, A. S.; Odejide, O. O.; Dahi, P. B.; Nieto, Y.; Joyce, R. M.; Chen, Y. B.; Bonjoc, K. J. C.; Chaudhry, A.; Herrera, A. F.; Armand, P.; Merryman, R. W. |
| Article Title: | Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation |
| Abstract: | Improved biomarkers are needed to guide patient selection for autologous stem cell transplantation (ASCT) and post-ASCT maintenance therapies in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the prognostic value of minimal residual disease (MRD) using immunoglobulin-based high-throughput sequencing (Ig-HTS), we analyzed pre- and post-ASCT peripheral blood and pre-ASCT apheresis stem cell (ASC) samples in 36 cHL patients. A tumor clonotype was detected in only 12 patients (33%). Among these patients, MRD within plasma samples was closely associated with impending relapse. All patients (n = 3) with detectable MRD in any post-ASCT plasma sample relapsed (100% specificity), and MRD was not detected in any patients in remission. MRD testing from cellular specimens (peripheral blood mononuclear cell or ASC samples) was not associated with relapse. In this small cohort, plasma-based MRD testing appeared to be a promising biomarker in cHL, but given low clonotype detection rates with Ig-HTS, alternative MRD approaches should be investigated. © 2022 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; clinical article; controlled study; human tissue; human cell; allogeneic stem cell transplantation; clinical feature; cancer recurrence; systemic therapy; cancer radiotherapy; follow up; antineoplastic agent; sensitivity and specificity; cancer immunotherapy; neoplasm recurrence, local; cohort analysis; autologous stem cell transplantation; stem cell transplantation; hematopoietic stem cell transplantation; pathology; retrospective study; cancer therapy; hodgkin disease; cancer regression; mononuclear cell; leukocytes, mononuclear; minimal residual disease; neoplasm, residual; tumor recurrence; false positive result; transplantation, autologous; predictive value; peripheral blood mononuclear cell; classical hodgkin lymphoma; adverse event; phase 2 clinical trial (topic); autotransplantation; clinical outcome; multicenter study (topic); metabolic tumor volume; cancer prognosis; high throughput sequencing; maintenance chemotherapy; brentuximab vedotin; palliative chemotherapy; humans; prognosis; human; male; female; article; pembrolizumab; monoclonal antibody therapy; circulating tumor dna (ctdna); stem cell apheresis |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 63 |
| Issue: | 12 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2022-01-01 |
| Start Page: | 2912 |
| End Page: | 2917 |
| Language: | English |
| DOI: | 10.1080/10428194.2022.2103808 |
| PUBMED: | 35938581 |
| PROVIDER: | scopus |
| PMCID: | PMC11165988 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2023 -- Source: Scopus |
